PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447016
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447016
According to Stratistics MRC, the Global Cough Syrup Market is accounted for $6312.09 million in 2023 and is expected to reach $8764.00 million by 2030 growing at a CAGR of 4.8% during the forecast period. An over-the-counter drug that is frequently used to treat cough symptoms is cough syrup. Cough syrup usually contains expectorants, cough suppressants, and occasionally antihistamines as active ingredients. Its main goals are to ease throat irritation, lessen the urge to cough, and encourage mucus loosening. Moreover, some formulations may also contain fever reducers or pain relievers. Cough syrup comes in a variety of forms, such as liquids and syrups, it is simple to use.
According to the American Lung Association, proper respiratory health is crucial for overall well-being, and regular exercise can contribute to maintaining strong lung function.
Frequency of respiratory conditions
Cough syrup demand is largely driven by the ongoing prevalence of respiratory conditions like colds, the flu, and allergies. Since many people throughout the world suffer from these illnesses, there is a constant need for cough relief products. Furthermore, cough syrup becomes the go-to option for people looking for quick and efficient relief from irritable symptoms related to respiratory problems.
Limited ability to address fundamental causes
Cough syrups mainly treat the symptoms of respiratory disorders rather than their underlying causes. Although they alleviate coughing and associated discomfort, they might not treat the underlying cause of the illness. Additionally, the need for therapies that provide comprehensive answers is growing among health-conscious consumers, which could limit the market for cough syrup expansion.
Growing need for children's cough syrups
There's a chance to create pediatric cough syrups specifically because of the growing awareness of pediatric health and the growing need for kid-friendly medications. Products with flavors that appeal to kids and dosages that are accurate can become popular on the market. Moreover, by catering to the particular needs and preferences of pediatric consumers, manufacturers can make significant profits from this market niche.
Price erosion and generic competition
The market for cough syrup is severely challenged by the possibility of generic competition. Cough syrups may see price erosion when generic versions hit the market after a patent expires. Additionally, the market share and profitability of well-known brands may be impacted by increased competition from generic alternatives, necessitating strategic planning on the part of businesses to maintain a competitive advantage.
The market for cough syrup has seen a variety of effects from the COVID-19 pandemic. Although there was initially a spike in demand for cough and cold remedies, such as cough syrups, due to the increased focus on respiratory health, the industry faced difficulties due to disruptions in supply chains, manufacturing, and distribution. Lockdowns, social distancing policies, and economic uncertainty affected consumer buying patterns, causing a move toward necessities and internet retailers. Furthermore, the pandemic increased people's awareness of the value of preventive care and general health, which may have an effect on how people feel about and use cough syrups.
The Cough Suppressants/Antitussives segment is expected to be the largest during the forecast period
The segment with the largest share is predicted to be cough suppressants and antitussives. Decongestants, like dextromethorphan, act by lessening the urge to cough, which relieves dry, ineffective coughs. This category appeals to a wide range of consumers because it effectively reduces cough symptoms without making people drowsy. Moreover, antitussives are frequently used in over-the-counter cough syrup formulations due to their targeted approach to treating persistent coughing, which drives demand for them.
The Online Pharmacy segment is expected to have the highest CAGR during the forecast period
The market's highest CAGR has been seen in the online pharmacy sector, which also includes over-the-counter drugs like cough syrups. Online pharmacies are becoming more and more popular due to factors like accessibility, convenience, and consumer preference for online shopping. Additionally, customers can access a multitude of options, compare products, and make purchases from the comfort of their homes with the help of the online platform. Due to social distancing measures, the COVID-19 pandemic has expedited the adoption of online pharmacies even more.
It is projected that North America will control the largest share of the cough syrup market. The area is distinguished by a sizable consumer base, a well-established healthcare infrastructure, and high healthcare awareness. There is a demand for cough syrups because respiratory conditions are more common, especially in the winter months. Furthermore, the market in North America is further supported by the presence of large pharmaceutical companies and consumer preferences for over-the-counter medications.
The cough syrup market is expected to grow at the highest CAGR in the European region. The area benefits from an aging population that is more susceptible to respiratory disorders, a well-established healthcare system, and high health awareness. Additionally, the wintertime cold and flu season's propensity to spread adds to the steady demand for cough syrups. Europe is positioned for continued growth in the cough syrup market due to its propensity for self-medication and over-the-counter remedies, as well as advances in pharmaceutical research.
Key players in the market
Some of the key players in Cough Syrup market include Takeda Pharmaceutical Company Limited, Abbott Laboratories, Johnson and Johnson Services, Inc, Merck & Co., Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd, Acella Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd., Novartis International AG, Reckitt Benckiser Group Plc., F. Hoffmann-La Roche Ltd, Sanofi, AstraZeneca PLC, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline PLC and Cipla Ltd.
In January 2024, Merck, a leading science and technology company, has announced a licensing agreement with US-based firm Inspirna, Inc. for ompenaclid, a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated advanced or metastatic colorectal cancer (mCRC).
In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.
In January 2023, Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary Hutchmed to develop and market the latter's fruquintinib. Under the deal terms, the company will have an exclusive global licence for the development and commercialisation of fruquintinib for all indications and territories outside of mainland China, Macau, and Hong Kong.